JP2015501833A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015501833A5 JP2015501833A5 JP2014546692A JP2014546692A JP2015501833A5 JP 2015501833 A5 JP2015501833 A5 JP 2015501833A5 JP 2014546692 A JP2014546692 A JP 2014546692A JP 2014546692 A JP2014546692 A JP 2014546692A JP 2015501833 A5 JP2015501833 A5 JP 2015501833A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- pharmaceutically acceptable
- acceptable salt
- optionally substituted
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 17
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- VHPXWPAGHGHDCK-UHFFFAOYSA-N 5-chloro-4-[(3,4-dichlorophenoxy)methyl]-2-fluoro-n-methylsulfonylbenzamide Chemical compound C1=C(F)C(C(=O)NS(=O)(=O)C)=CC(Cl)=C1COC1=CC=C(Cl)C(Cl)=C1 VHPXWPAGHGHDCK-UHFFFAOYSA-N 0.000 claims 3
- 229940124777 Nav1.7 inhibitor Drugs 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims 1
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006625 (C3-C8) cycloalkyloxy group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 230000003040 nociceptive effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161576005P | 2011-12-15 | 2011-12-15 | |
| US61/576,005 | 2011-12-15 | ||
| PCT/IB2012/057035 WO2013088315A1 (en) | 2011-12-15 | 2012-12-06 | Sulfonamide derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015501833A JP2015501833A (ja) | 2015-01-19 |
| JP2015501833A5 true JP2015501833A5 (enExample) | 2016-01-21 |
| JP6058023B2 JP6058023B2 (ja) | 2017-01-11 |
Family
ID=47557422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014546692A Expired - Fee Related JP6058023B2 (ja) | 2011-12-15 | 2012-12-06 | スルホンアミド誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9085517B2 (enExample) |
| EP (1) | EP2791108B1 (enExample) |
| JP (1) | JP6058023B2 (enExample) |
| CA (1) | CA2857603C (enExample) |
| ES (1) | ES2593533T3 (enExample) |
| WO (1) | WO2013088315A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2773641B1 (en) | 2011-10-31 | 2017-09-27 | Xenon Pharmaceuticals Inc. | Biaryl ether sulfonamides and their use as therapeutic agents |
| WO2013064983A1 (en) | 2011-10-31 | 2013-05-10 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| CA2860553C (en) * | 2012-01-04 | 2016-08-23 | Pfizer Limited | N-aminosulfonyl benzamides |
| SG11201408284VA (en) | 2012-05-22 | 2015-02-27 | Xenon Pharmaceuticals Inc | N-substituted benzamides and their use in the treatment of pain |
| US10071957B2 (en) | 2012-07-06 | 2018-09-11 | Genentech, Inc. | N-substituted benzamides and methods of use thereof |
| RU2015143906A (ru) | 2013-03-14 | 2017-04-18 | Дженентек, Инк. | Замещенные триазолопиридины и способы их применения |
| US9493429B2 (en) | 2013-03-15 | 2016-11-15 | Genentech, Inc. | Substituted benzoxazoles and methods of use thereof |
| AU2014356967A1 (en) | 2013-11-27 | 2016-07-07 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| JP2017525677A (ja) | 2014-07-07 | 2017-09-07 | ジェネンテック， インコーポレイテッド | 治療用化合物及びその使用方法 |
| BR112017024853A2 (pt) | 2015-05-22 | 2018-08-07 | Genentech Inc | composto, composição farmacêutica, método para tratar uma doença ou condição em um mamífero, para tratamento de prurido em um mamífero, para tratamento ou profilaxia e uso de um composto |
| MA42683A (fr) | 2015-08-27 | 2018-07-04 | Genentech Inc | Composés thérapeutiques et leurs méthodes utilisation |
| SG10202007787RA (en) | 2015-09-28 | 2020-09-29 | Genentech Inc | Therapeutic compounds and methods of use thereof |
| MY194015A (en) | 2015-11-13 | 2022-11-08 | Daewoong Pharmaceutical Co Ltd | Sodium channel blocker |
| JP2018535234A (ja) | 2015-11-25 | 2018-11-29 | ジェネンテック， インコーポレイテッド | ナトリウムチャネル遮断薬として有用な置換ベンズアミド |
| WO2017172802A1 (en) | 2016-03-30 | 2017-10-05 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| SG11201903348UA (en) | 2016-10-17 | 2019-05-30 | Genentech Inc | Therapeutic compounds and methods of use thereof |
| CN110546148A (zh) | 2017-03-24 | 2019-12-06 | 基因泰克公司 | 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物 |
| CN111132961A (zh) | 2017-08-31 | 2020-05-08 | 拉夸里亚创药株式会社 | 作为ttx-s阻断剂的双芳氧基衍生物 |
| EP3759098A1 (en) | 2018-02-26 | 2021-01-06 | Genentech, Inc. | Pyridine-sulfonamide compounds and their use against pain and related conditions |
| TWI903299B (zh) | 2018-03-08 | 2025-11-01 | 美商英塞特公司 | 作為PI3K-γ抑制劑之胺基吡嗪二醇化合物 |
| CN111936494A (zh) | 2018-03-30 | 2020-11-13 | 豪夫迈·罗氏有限公司 | 作为钠通道抑制剂的取代的氢-吡啶并-吖嗪 |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| CN113164461A (zh) * | 2018-12-26 | 2021-07-23 | 拉夸里亚创药株式会社 | 作为Nav1.7及Nav1.8阻断剂的杂环衍生物 |
| JPWO2021132577A1 (enExample) * | 2019-12-27 | 2021-07-01 | ||
| CN113200956B (zh) * | 2021-05-18 | 2022-04-22 | 潍坊医学院 | 一种磺胺苯甲酰胺类衍生物及其制备方法和应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| JPH05289262A (ja) | 1992-04-10 | 1993-11-05 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
| ES2141197T3 (es) | 1993-03-19 | 2000-03-16 | Merck & Co Inc | Derivados del acido fenoxifenilacetico. |
| CA2195758A1 (en) | 1994-08-08 | 1996-02-22 | Scott W. Bagley | Phenoxyphenylacetic acid derivatives |
| WO1996009818A1 (en) | 1994-09-27 | 1996-04-04 | Merck & Co., Inc. | Endothelin receptor antagonists for the treatment of emesis |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| GB9828442D0 (en) | 1998-12-24 | 1999-02-17 | Karobio Ab | Novel thyroid receptor ligands and method II |
| EP1357908A4 (en) | 2001-01-30 | 2009-07-15 | Merck & Co Inc | "ACYLSULFAMIDES FOR THE TREATMENT OF FATIBILITY, DIABETES AND LIPID DISORDERS" |
| KR20060073930A (ko) | 2003-08-08 | 2006-06-29 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료시 나트륨 또는 칼슘 채널 차단제로서 유용한헤테로아릴아미노설포닐페닐 유도체 |
| CA2536954C (en) | 2003-08-29 | 2012-11-27 | Exelixis, Inc. | C-kit modulators and methods of use |
| GB0423554D0 (en) | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
| WO2008008234A1 (en) | 2006-07-07 | 2008-01-17 | Targegen, Inc. | 2-amino-5-substituted pyrimidine inhibitors |
| SI2076508T1 (sl) | 2006-10-18 | 2011-04-29 | Pfizer Prod Inc | Spojine biaril eter sečnine |
| JP5361857B2 (ja) | 2007-03-23 | 2013-12-04 | ファイザー・リミテッド | イオンチャネルの阻害剤 |
| WO2008135826A2 (en) | 2007-05-03 | 2008-11-13 | Pfizer Limited | 2 -pyridine carboxamide derivatives as sodium channel modulators |
| WO2009012242A2 (en) | 2007-07-13 | 2009-01-22 | Icagen, Inc. | Sodium channel inhibitors |
| GB0725214D0 (en) | 2007-12-24 | 2008-02-06 | Karobio Ab | Pharmaceutical compounds |
| JP2011520897A (ja) | 2008-05-16 | 2011-07-21 | シェーリング コーポレイション | グルカゴン受容体アンタゴニスト、組成物およびそれらの使用方法 |
| RU2563639C2 (ru) * | 2009-09-25 | 2015-09-20 | Астеллас Фарма Инк. | Замещенные соединения амида |
| JP5289262B2 (ja) | 2009-09-30 | 2013-09-11 | 京セラドキュメントソリューションズ株式会社 | シート搬送装置とこれを備えた画像読取装置及び画像形成装置 |
| WO2011070592A2 (en) | 2009-12-09 | 2011-06-16 | Panacea Biotec Ltd. | Novel sugar derivatives |
| JP2013519685A (ja) | 2010-02-11 | 2013-05-30 | ヴァンダービルト ユニバーシティー | ｍＧｌｕＲ４アロステリック増強剤としてのベンズイソオキサゾール類およびアザベンズイソオキサゾール類、組成物、および神経機能不全を治療する方法 |
| PH12012501621A1 (en) | 2010-02-11 | 2012-10-22 | Univ Vanderbilt | Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| CN103025740B (zh) | 2010-04-16 | 2015-07-01 | 梅特希尔基因公司 | 蛋白酪氨酸激酶活性的抑制剂及其治疗眼科疾病的用途 |
| US9102621B2 (en) * | 2010-07-12 | 2015-08-11 | Pfizer Limited | Acyl sulfonamide compounds |
| WO2012007868A2 (en) * | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
| US10071957B2 (en) * | 2012-07-06 | 2018-09-11 | Genentech, Inc. | N-substituted benzamides and methods of use thereof |
-
2012
- 2012-12-06 WO PCT/IB2012/057035 patent/WO2013088315A1/en not_active Ceased
- 2012-12-06 EP EP12813989.6A patent/EP2791108B1/en not_active Not-in-force
- 2012-12-06 CA CA2857603A patent/CA2857603C/en not_active Expired - Fee Related
- 2012-12-06 US US14/358,494 patent/US9085517B2/en not_active Expired - Fee Related
- 2012-12-06 JP JP2014546692A patent/JP6058023B2/ja not_active Expired - Fee Related
- 2012-12-06 ES ES12813989.6T patent/ES2593533T3/es active Active